Pathological Features, Treatment Options and Prognosis Assessment of Patients with Bone Lymphoma in Real-World.
- Author:
Jin-Ping OU
1
;
Shuang GAO
1
;
Li-Hong WANG
1
;
Jian-Hua ZHANG
1
;
Lin NONG
1
;
Wei LIU
1
;
Wen-Sheng WANG
1
;
Yu-Hua SUN
1
;
Wei-Lin XU
1
;
Yue YIN
1
;
Ze-Yin LIANG
1
;
Qian WANG
1
;
Yuan LI
1
;
Yu-Jun DONG
1
;
Qing-Yun WANG
1
;
Mang-Ju WANG
1
;
Bing-Jie WANG
1
;
Zhi-Xiang QIU
1
;
Xi-Nan CEN
2
;
Han-Yun REN
1
Author Information
- Publication Type:Journal Article
- MeSH: Bone Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies
- From: Journal of Experimental Hematology 2019;27(3):796-801
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical manifestations pathologic features, treatment options and prognosis of patients with bone lymphoma.
METHODS:The clinical characteristics, pathologic features, treatment and prognosis of 34 BL patients diagnosed by histopathologic method or/and PET-CT and treated in first hospital of peking university from January 2004 to April 2018 were analyzed retrospectively.
RESULTS:The median age of 34 BL patients was 56 years old, the male and female ratio was 1.43∶1 (24 /10). Among 34 patients, the patients with primary bone lymphoma(PBL) were 8 cases, the patients with secondary bone lymphoma(SBL) was 26 cases, the PBL and SBL ratio was 0.31∶1. Bone lymphoma lacks typical systemic symptoms, and its onset began mostly from bone pain and pathologic bone fracture. The most frequent pathological type of bone lymphoma in our study was diffuse large B-cell lymphoma (DLBCL), accounting for 55.88%. At present, the conventional treatment for bone lymphoma includes chemotherapy, or chemotherapy combined with radiotherapy and surgery, as well as hematopoietic stem cell transplantation. The average and median OS time of BL patients were 349 years and 3 years respectively, meanwhile the OS rate for three years and two years were 56.25% and 78.16%, respectively. Factors that affect survival of BL patients were PBL and SBL classification, pathological type, blood LDH level, and treatment methods.
CONCLUSION:Bone lymphoma is usually concealed onset，an adequate and adequate combination therapy can improve the survival rate and transplantation therapy plays an important role. Primary bone lymphoma is rare, the prognosis of patients with primary bone lymphoma is good, whereas the prognosis of patients with secondary bone lymphoma is poor.
